$OPRX News

Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est

OptimizeRx Q2 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $20.504M Beat $20.204M Estimate

OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

OptimizeRx Rolls Out CopayCue To Provide Enhanced Brand Savings For Physicians

OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms

OptimizeRx (OPRX) Stock Sees Fair Value Cut As Analysts Reset Growth Expectations

OptimizeRx: A Good Business That Has Not Yet Earned Back Investor Trust

OptimizeRx to Participate in Upcoming Investor Conferences

DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx’s Authenticated EHR Network

OptimizeRx's Electronic Health Record Network Integrated By DeepIntent

Some OptimizeRx Corporation (NASDAQ:OPRX) Analysts Just Made A Major Cut To Next Year's Estimates

OptimizeRx (OPRX) Q1 2026 Earnings Transcript

Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $11

B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10

Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7

Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14